Latest Cancer Immunotherapy News

Invion Limited’s partner Hanlim Pharm, backed by South Korea’s government grant, has secured up to A$2 million in non-dilutive funding to advance preclinical studies of HL270 for oesophageal cancer, paving the way for human trials in Australia.

Immutep has struck a strategic licensing deal with Dr. Reddy’s, granting rights to commercialise its novel cancer immunotherapy Eftilagimod Alfa across key emerging markets. The agreement includes a $20 million upfront payment and potential milestones exceeding $349 million.

Imugene Limited and JW Therapeutics have launched a strategic collaboration to combine oncolytic virus and CAR-T cell therapies, aiming to tackle refractory solid tumors through a pioneering 'mark and kill' approach.

Noxopharm Limited has been granted its first US patent for the Sofra™ technology platform, marking a key milestone in its cancer immunotherapy research. This patent protects the company’s innovative immune-modulatory oligonucleotides, underpinning its expanding pipeline in a rapidly growing market.

Immutep Limited has confirmed 30 mg as the optimal biological dose for its immunotherapy efti, following FDA approval of Project Optimus requirements. This milestone paves the way for the US launch of its pivotal Phase III lung cancer trial.

Arovella Therapeutics has demonstrated that its novel CLDN18.2 CAR-T cells effectively eliminate pancreatic cancer cells in vitro, matching the performance of a leading competitor’s product. The company is now advancing this CAR into its innovative iNKT cell platform to tackle solid tumours.

Prescient Therapeutics has extended the closing date of its Share Purchase Plan to July 25, 2025, responding to shareholder demand and reinforcing strong participation. The oncology-focused biotech also highlights upcoming clinical milestones and ongoing investor engagement.

Prescient Therapeutics has extended its Share Purchase Plan closing date to 22 July 2025, aiming to raise up to A$7 million to advance its targeted cancer therapy PTX-100 through Phase 2 clinical trials.

Invion Limited reports no adverse events and early lesion reduction in its Phase I/II non-melanoma skin cancer trial, advancing to dose optimization.

Imugene Limited reports durable patient responses in multiple cancer immunotherapy trials and strengthens its financial position with a $46 million convertible note deal and a substantial R&D tax refund.

Imugene Limited has secured A$20 million through convertible notes as part of a broader A$46 million capital raise, aiming to advance its promising immuno-oncology pipeline.